Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Header Top Menu

  • Careers
  • Investors
  • News
    • Press Release Archive
    • Press Statements
    • Podcasts
      • The Antigen Podcast
      • Get Science Podcast
      • Diverse Perspectives Podcast
      • menopause: unmuted
    • Contact Media Relations
    • Press Kits & Downloads
      • Company Press Kit
      • Pfizer Oncology Press Kit
      • PSA Narrative
      • RA NarRAtive
      • Rare Disease Gene Therapy Press Kit
      • ATTR-Amyloidosis Press Kit
      • UC Narrative
      • Eczema Inside Out Press Kit
  • Partners
    • Discovery to Pre-candidate
      • Focus Areas
        • Therapeutic Areas
          • Internal Medicine
          • Inflammation and Immunology
          • Oncology
          • Rare Disease
          • Vaccines
        • Therapeutic Modalities and Technology Platforms
          • Drug Safety
          • Gene Therapy
          • Target Sciences
          • Precision Medicine
          • Medicinal Sciences
            • Biologics Product & Process Development
            • Biotherapeutics Discovery
            • Medicine Design
            • Small Molecule Product & Process Development
        • Emerging Science
          • DNA Damage Response
          • Microsatellite Repeat Expansions
          • Senescence
      • Partnering Models
    • Candidate Through Commercialization
      • Focus Areas
        • Internal Medicine
        • Inflammation and Immunology
        • Oncology
        • Rare Disease
        • Vaccines
        • Hospital
    • Pfizer CentreOne
    • Pfizer Ventures
      • Our portfolio

Healthcare Professionals

  • Healthcare Professionals

Connect with Us

  • Connect with Us
    • Email
    • FAQ
    • Privacy Policy (NEW)
    • YouTube
    • Twitter
    • Facebook
    • LinkedIn
    • Instagram
  • Your Health

    • Healthy Living
      • Brain & Nervous System
      • Cardiovascular Health
      • Cold & Flu
      • Digestive Health
      • Healthier Aging
      • Living Tobacco Free
      • Men’s Health
      • Mental Health
      • Nutrition & Fitness
      • Pediatric Health
      • Respiratory Health
      • Skin Health
      • Vaccines & Prevention
      • Women’s Health

    • Disease & Condition
      • Cancer
      • Cardiovascular Diseases & Conditions
      • Diabetes & Metabolic Disorders
      • Immune System Diseases & Conditions
      • Infections & Infectious Diseases
      • Neurological Diseases & Conditions
      • Menopause
      • Rare Disease
      • Vaccine-Related Conditions
      • Skin Diseases & Conditions
      • Atopic Dermatitis

    • Coronavirus disease (COVID-19)

    • Managing your health
      • Caregiving
      • Evaluating Health Information
      • Tracking Your Health
      • Your Medicines
      • Health Literacy

    • Wellness
    Hot Topics

    Maintaining Emotional Well-Being During COVID-19

    Emotional Well-Being Tips for People Living with Chronic Inflammatory Conditions During COVID-19
  • Our Science

    • Driven to Discover the cure

    • Focus Areas
      • Internal Medicine
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Anti Infectives

    • Product Pipeline

    • Clinical Trials
      • Guide to Clinical Trials
      • Find a Trial
      • Expanded Access & Compassionate Use
      • Clinical Trials in Children
      • Partnering with Pfizer
      • Trial Data & Results
      • Research Integrity & Transparency
      • Diversity in Clinical Trials

    • R&D Platforms
      • Biosimilars
      • Gene Therapy
      • Medicinal Sciences
      • Precision Medicine
      • Maternal Immunization

    • Collaboration
      • Partner with Pfizer

    • Research sites

    • Coronavirus disease (COVID-19) Scientific Resources
    HOT TOPICS

    MRNA VS. CONVENTIONAL VACCINES

    What Makes an RNA Vaccine Different From a Conventional Vaccine?
  • Our People

    • Meet The Experts
      • Scientists
      • Internal Medicine – Metabolic Disease
      • Inflammation & Immunology
      • Oncology
      • Rare Disease
      • Vaccines
      • Medical Professionals

    • The Journey

    • Leadership
      • Executives
      • Board Members
      • Company Fact Sheet

    • Diverse Perspectives
      • Diversity & Inclusion
      • Supplier Diversity
    HOT TOPICS

    Meet our new Chief Patient Officer, Dr. Dara Richardson-Heron

    dr_richardson_300x170.jpg

    Working Together to Empower Women

    VizagWomen_300x170.jpg

    • Hot Topics
  • Our Purpose

    • Commitment to Global Health
      • Expanding Access
      • Strengthening Health Systems
      • Providing Disaster & Humanitarian Relief
      • Unleashing the Power of Our Colleagues
      • Highlighting Individual Voices

    • Protecting People and the Environment
      • Pfizer's Green Journey
      • Product Stewardship
      • EHS Governance
      • EHS Supply Chain
      • Key Performance Indicators
      • Health & Safety
      • Human Rights

    • Positions on Health Policies
      • Ready for Cures
      • How does Pfizer price medicines?
      • Value of Medicines
      • Policy Positions
      • Creating Cures Through Facility Investments

    • Transparency
      • Working with Health Care Professionals
      • Transparency in Grants
      • Code of Conduct
      • Corporate Compliance
      • Sales and Marketing Compliance

    • Independent Grants
      • Competitive Grants Program
      • Independent Medical Education
      • Investigator Sponsored Research
      • Quality Improvement
      • COVID-19 Vaccine Grants

    • Contributions & Partnerships
      • Healthcare Charitable Contributions
      • Lobbying & Political Contributions
    HOT TOPICS

    Pfizer Women’s Resource Group

    Media Name: IWD_Pull_up_Banner_300x170.jpg

    • Hot Topics
  • Our Products

    • Product listing

    • How drugs are made
      • Branded vs. Generic
      • Biologics & Biosimilars
      • Commitment to Quality

    • Distributors
      • Pfizer Distributors
      • Greenstone Distributors

    • Medicine Safety
      • Reporting Adverse Events
      • Making Good Treatment Choices
      • Partnering With Patients
      • Health Literacy
      • Medicine Safety Tips for Patients
      • Counterfeiting
      • Unused Medicines

    • Safety Data Sheets

    • Medical Information Contacts

    • Pfizer Global Supply
    HOT TOPICS

    Universal vs. Single Payer Healthcare

    Media Name: universal_healthcare300x170.jpg
  • Careers

    • Working Here
      • Mission & Purpose
      • Culture
      • Diversity & Inclusion
      • Career Growth & Colleague Development
      • Compensation & Benefits
      • Ensuring Corporate Responsibility
    • Search Jobs
    • Student & Early Career
      • Postdoctoral Program
      • US Summer Student Worker Program
      • Opportunities for Veterans
    • Pfizer365.com
    • Our Hiring & Recruiting Process
      • Frequently Asked Questions
      • Tips for Interviewing at Pfizer
    • Connect With Us
  • Investors

    • Investors Overview
      • Why Invest / Our Story
      • Prospective Investors
      • Fact Sheet
    • Events & Presentations
    • Financials
      • Quarterly Reports
      • Annual Reports
      • SEC Filings
      • Interactive Data Filings
    • Investor News
    • Stock Information
      • Historical Price Lookup
      • Investment Calculator
      • Historical Stock Chart & Data
      • Dividend & Split History
      • Stock FAQs
    • Governance
      • Board Committees and Charters
      • The Pfizer Board Policies
      • Corporate Governance FAQs
      • Contact Our Directors
    • Shareholder Services
      • Stock FAQs
      • Advisory Information
      • Cost Basis Calculator
  • News

    • Contact Media Relations
    • Podcasts
    • Press Kits & Downloads
    • Press Release Archive
    • Press Statements
  • Partners
  • Footer links

    • Footer Aside Section1
      • CAREER-SEEKERS
      • INVESTORS
      • News & Media
      • Partners
    • Footer Aside Section 2
      • Healthcare Professionals
      • Business To Business
      • Change Region
      • Sitemap
    • Footer Aside Section3
      • Twitter
      • Facebook
      • Linkedin
      • Instagram
      • Youtube
    • Footer Aside Section4
      • Contact Us
      • Terms of Use
      • Privacy Policy

Pfizer commits to public-private partnership to train community health workers in up to six African countries

Pfizer commits to public-private partnership to train community health workers in up to six African countries
OUR PURPOSE/ Pfizer commits to public-private partnership to train community health workers in up to six African countries
January 16, 2020

Pfizer has a long-standing commitment to improving access to healthcare and reducing healthcare disparities across the globe. To advance progress and impact, we partner with foundations, civil society groups and other biopharmaceutical companies to drive progress toward our shared goals.

Today we are proud to announce our involvement in the Health Worker Training Initiative, a three-year investment to train and equip community health workers and increase access to community-based primary healthcare in up to six African countries.

Led by Last Mile Health and Living Goods, the Health Worker Training Initiative is a collaboration with GlaxoSmithKline, Johnson & Johnson, Lilly, Novartis, and the Bill & Melinda Gates Foundation. The initiative is designed to leverage the combined resources and specific expertise of these organizations to expand the integral role that community health workers can play in providing access to healthcare for nearly 1.7 million people and advancing progress toward universal health coverage.

Pfizer is proud to provide resources and support for the Health Worker Training Initiative over the next three years (2020-2023). The collaboration will help improve the effectiveness and impact of community health workers around the world, allowing them to reach more patients and build stronger health programs for the future using digital tools. 

Efforts to improve access to and reduce disparities in global healthcare benefit from cross-sectoral collaboration, and Pfizer is committed to working alongside other change agents within – and outside of – our industry to improve health outcomes worldwide.

Read the press release:

Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People

Healthcare companies and philanthropies to fund training of thousands of community health workers as part of larger initiative led by Last Mile Health and Living Goods to advance universal health coverage

[BASEL, SWITZERLAND 9:00 A.M. CET/NEW YORK, NEW YORK 3:00 A.M. EST - 16 January 2020] –  Johnson & Johnson, Lilly, Novartis, Pfizer, GSK and the Bill & Melinda Gates Foundation have joined forces with Last Mile Health and Living Goods to increase access to community-based primary healthcare for nearly 1.7 million people in up to six African countries, as part of their shared commitment to accelerate universal health coverage. The Health Worker Training Initiative is a three-year investment, generously matched by The Audacious Project, and totals USD $18 million.

Harnessing the synergy of cross-industry collaboration is key to advancing universal health coverage. Living Goods and Last Mile Health have pioneered the community health worker model and are continually exploring novel approaches to training and retaining community health workers. By teaming up with Johnson & Johnson, Lilly, Novartis, Pfizer, GSK and the Bill & Melinda Gates Foundation, precious resources and acumen can be maximized. All are united by the belief that community health workers play a catalytic role, and all share a commitment towards advancing universal health coverage.

Leveraging the unique expertise of each organization will drive tech innovation and deepen impact. In addition to financial contributions, industry partners will contribute disease-specific expertise and experience in the discovery and development of new tools, which will supplement the community health worker models pioneered by Last Mile Health and Living Goods, in partnership with government.

Investing in community health workers produces some of the best returns in health. Community health workers can yield a 10:1 return on investment, due to a healthier population, increased employment, and lower odds of health crises. In addition, community health workers can help primary healthcare systems serve the majority of a population’s health needs, which means community health workers are one of the most efficient and effective ways to achieve universal health coverage. This partnership is a response to the growing call to action globally to advance universal health coverage and Sustainable Development Goal 3.

“Focused investment in community health workers can accelerate progress to make universal health coverage a reality,” said Dave Ricks, chairman and CEO of Lilly and president of the International Federation of Pharmaceutical Manufacturers & Associations. “Public-private collaboration is critical to help governments lower barriers to quality care and innovative medicines that save and improve people’s lives.”

“Community health workers are the critical frontline to sustainably impact the health of communities in resource poor settings,” said Vas Narasimhan, CEO of Novartis.  “Novartis is committed to strengthening healthcare systems and is proud to be part of this coalition to use digital technologies to reimagine the future of community health delivery.”

The three-year investment will cover three areas:

  • Supporting the training and deployment of 2,500 digitally-enabled community health workers, reaching nearly 1.7 million people by 2022. Community health workers will be trained and deployed in Liberia, Kenya, Uganda, Malawi and up to two additional
  • Supporting Last Mile Health’s Community Health Academy, which is an open source, digital learning platform for community health workers and health systems leaders used worldwide. Training curricula for community health workers initially focuses on diarrheal diseases, family planning, malaria and pneumonia, with further modules expected to address non-communicable diseases, such as diabetes and hypertension.
  • Contributing expertise and personnel to Living Goods’ new Kenya Performance Lab to develop mobile-based tech innovations that will improve community health worker productivity, strengthen supply chains and better identify obstacles to coverage. The Lab will leverage the knowledge and assets of partners in areas including data science, behavior change, performance management, analytics and technical health expertise. Innovations would be introduced in Kenya and then scaled to other countries within the broader initiative.

Together, these pieces of the investment aim to scale up access to life-saving primary healthcare while building stronger, tech-enabled community health programs for the future.

“Well-trained community health workers play an integral role in providing quality care in low-resource settings,” said Andrin Oswald, Co-chair of the CEO Roundtable Executive Council and Director of Life Sciences Partnerships at the Bill & Melinda Gates Foundation. “The Gates Foundation is committed to working with partners across sectors to achieve universal health coverage, which is necessary to achieving the Sustainable Development Goals and reducing the burden of diseases that disproportionately affect pregnant women and young children. We thank the companies involved in this initiative for their efforts to increase data-driven solutions to train and deploy effective community health workers.”

“This partnership will play a critical role in helping to scale and empower the world’s most promising health resource—community health workers—so that they can thrive and effectively save lives,” said Dr. Jane Aceng, Uganda’s Minister of Health. “Ensuring community health workers have the right training, digital technology, medical equipment and supervision is critical for ensuring they can help transform health outcomes, no matter where people live.”

Each of the six investors will contribute USD $1.5 million total over the next three years. This funding will be matched by the Audacious Project through an existing USD $50 million matching commitment to scale community health workers in Africa, resulting in an USD $18 million total investment.

This investment will also support the sustainability of community health worker programs. Living Goods and Last Mile Health partner with governments to deploy digitally-empowered community health workers. Not only will this partnership support community health workers to reach more patients, but the curricula and tools developed through the investment will support improved community health worker performance for years to come.

“We are inspired that healthcare companies are taking collective action to strengthen community health systems in the public sector across sub-Saharan Africa to advance universal health coverage,” said Liz Jarman, CEO of Living Goods, and Dr. Raj Panjabi, CEO of Last Mile Health. “This partnership is much more than a financial commitment; it joins a growing movement of philanthropists, companies, and governments that have committed to scale digitally-empowered community health workers and build stronger primary healthcare systems across Africa to ultimately save more lives."

To learn more about the community health movement and efforts to advance universal health coverage in partnership with governments, watch this video produced by Freethink.

 

 

Related Hot Topics
Advancing Health Equity & Social Justice Through Community Investment
Advancing Health Equity & Social Justice Through Community Investment
Pfizer_JonxPillemer_Kenya_2016-1355_380X200.jpg
The Pfizer Foundation Invests in Community-Based Solutions to Combat the Threat…
Moving at the Speed of Science
Moving at the Speed of Science
Woman-Made: Hear from Women at Pfizer With Careers in Modern Manufacturing
Woman-Made: Hear from Women at Pfizer With Careers in Modern Manufacturing
Meet Our Manufacturers Inspiring Future Creators
Meet Our Manufacturers Inspiring Future Creators
How Pfizer and BioNTech are Moving with Safety and Speed to Develop a Potential COVID-19 Vaccine
How Pfizer and BioNTech are Moving with Safety and Speed to Develop a Potential…
Collaborating to Provide Lifesaving Cancer Treatments to Patients in Africa
Collaborating to Provide Lifesaving Cancer Treatments to Patients in Africa
Pfizer Partners with Wellcome to Combat Antimicrobial Resistance in Sub-Saharan Africa
Pfizer Partners with Wellcome to Combat Antimicrobial Resistance in Sub-Saharan…
Tags
Access
Partnerships
Responsibility
Technology
Show
Hide

Footer menu

  • Your Health
    • Healthy Living
    • Disease Conditions
    • Manage Your Health
  • Our Science
    • Therapeutic Areas
    • Product Pipeline
    • Clinical Trials
    • R&D Platforms
    • Collaboration
    • Research SItes
  • Our People
    • Meet the Experts
    • The Journey
    • Leadership
    • Diverse Perspectives
  • Our Purpose
    • Commitment To Global Health
    • Positions on Health Policies
    • Transparency
    • Contributions & Partnerships
  • Our Products
    • Product Listing
    • How Drugs are Made
    • Distributors
    • Global Product Information Contacts

Footer aside

  • Footer Aside Section1
    • CAREER-SEEKERS
    • INVESTORS
    • News & Media
    • Partners
  • Footer Aside Section 2
    • Healthcare Professionals
    • Business To Business
    • Change Region
    • Sitemap
  • Footer Aside Section3
    • Twitter
    • Facebook
    • Linkedin
    • Instagram
    • Youtube
  • Footer Aside Section4
    • Contact Us
    • Terms of Use
    • Privacy Policy
Pfizer Logo Footer

Copyright © 2002-2021 Pfizer Inc. All rights reserved. This information—including product information—is intended only for residents of the United States.
The products discussed herein may have different labeling in different countries.